letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...7475767778798081828384...100101»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Verapamil as a culprit of palbociclib toxicity. (Pubmed Central) -  Apr 26, 2019   
    Labs normalized upon discontinuation of verapamil and our patient was able to continue treatment with palbociclib and letrozole. Verapamil's inhibition of both permeability-glycoprotein (P-gp) and CYP3A4 is suspected to have led to the adverse side effects seen in our patient.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Trial completion date:  Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4) (clinicaltrials.gov) -  Apr 26, 2019   
    P3,  N=2056, Active, not recruiting, 
    Given the lack of head-to-head clinical trials comparing the efficacy of recently approved first-line ETs for HR+/HER2- mBC, these results have important clinical implications for the treatment of HR+/HER2- mBC in the first-line setting. Trial completion date: Aug 2018 --> Aug 2019
  • ||||||||||  hydrocortisone / Generic mfg., flutamide / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=62, Active, not recruiting, 
    Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020 Completed --> Active, not recruiting | Trial completion date: Jan 2017 --> Dec 2020 | Trial primary completion date: Jan 2017 --> Dec 2020
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    Preclinical, Journal:  Acquired-resistance to aromatase inhibitors: where we stand! (Pubmed Central) -  Apr 19, 2019   
    Moreover, clinical evidence demonstrated that there is a lack of cross-resistance among AIs, although the reason is not fully understood. Thus, there is a demand to understand the mechanisms involved in endocrine resistance to each AI, since the search for new strategies to surpass breast cancer acquired resistance is of major concern.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) -  Apr 17, 2019   
    P3,  N=900, Recruiting, 
    Trial completion date: Nov 2024 --> Feb 2024 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Tamoxis (tamoxifen) / Bioprofarma, Faslodex (fulvestrant) / AstraZeneca
    Clinical, Journal:  Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature. (Pubmed Central) -  Apr 16, 2019   
    The present case is the first one with complete and stable response after 20 months to radiotherapy, antiestrogen drug fulvestrant and selective inhibitor of CDK4 /CDK6 palbociclib. In this subset of patients, with unusual metastatic sites and frequent multi-organ metastatic impairment, a multidisciplinary approach is indicated in order to achieve the best therapeutic management and long-term surveillance.
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Trial completion:  Combined Letrozole and Clomid in Women With Infertility and PCOS (clinicaltrials.gov) -  Apr 16, 2019   
    P4,  N=70, Completed, 
    In this subset of patients, with unusual metastatic sites and frequent multi-organ metastatic impairment, a multidisciplinary approach is indicated in order to achieve the best therapeutic management and long-term surveillance. Active, not recruiting --> Completed
  • ||||||||||  letrozole / generics
    Clinical, Journal:  A Case of Multiple Lung Metastases from Breast Cancer Successfully Treated with Endocrine Therapy (Pubmed Central) -  Apr 13, 2019   
    After that, we modified the regimen to monotherapy of letrozole, and she achieved PR for a further 3 years. In the treatment for patients with metastatic hormone receptor-positive breast cancer, it is important to consider the sensitivity of endocrine therapy, such as relapse-free survival or the expression of hormone receptors in metastatic tumors.
  • ||||||||||  metformin / generics
    Clinical, Review, Journal:  Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. (Pubmed Central) -  Apr 11, 2019   
    We suggest weighing costs and convenience in the decision to use one or the other gonadotrophin. In women with clomiphene citrate failure, gonadotrophins resulted in more live births than continued clomiphene citrate without increasing multiple pregnancies.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal:  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. (Pubmed Central) -  Apr 11, 2019   
    To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) -  Apr 10, 2019   
    P4,  N=252, Active, not recruiting, 
    Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future. Trial completion date: Sep 2020 --> Sep 2019 | Trial primary completion date: Sep 2020 --> Sep 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial primary completion date:  COAT: Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy (clinicaltrials.gov) -  Apr 9, 2019   
    P2,  N=300, Active, not recruiting, 
    EA at ST 36, SP 6, and CV 4 all can improve the hyperandrogenism and ovarian polycystic morphological changes of PCOS rats, while different acupoints have different functional characteristics. Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Feb 2019
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica, Tamoxis (tamoxifen) / Bioprofarma, hydroxychloroquine / VG Lifesciences
    Clinical, Journal:  Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature. (Pubmed Central) -  Apr 7, 2019   
    We discussed the possible role of anastrazole treatment in inducing APS in our patient, reporting the available literature data about the association between AIs treatment and autoimmune diseases. Furthermore, we analyzed the mechanism of action of estrogens in the pathophysiology of autoimmune rheumatic disorders.
  • ||||||||||  letrozole / generics
    Preclinical, Journal:  Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice. (Pubmed Central) -  Mar 29, 2019   
    Our results indicate the potential anticonvulsant effects of letrozole against KA-induced seizures in mice that might be mediated by inhibiting aromatization of testosterone to 17β-estradiol, a proconvulsant hormone and by redirecting the synthesis to anticonvulsant metabolites, 5α-DHT and 3α-Diol. Acute aromatase inhibition, thus, might be used as an adjuvant in the treatment of status epilepticus and can be pursued further.
  • ||||||||||  metformin / generics
    Journal:  Ovulation induction in polycystic ovary syndrome. (Pubmed Central) -  Mar 29, 2019   
    Second line treatments are ovarian electrocautery and low-dose follicle stimulating hormone stimulation. Controlled ovarian stimulation with in vitro fertilization, should be considered the last option since it carries a significant risk of ovarian hyperstimulation syndrome in patients with PCOS.